Clinical Trial Search

Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity

Primary: Goal Attainment Scale - Modified (GAS): Responder (Score of 3 - Goal Achieved) vs. Non-Responder (Score of 1 or 2 - Goal NOT Achieved) — 29; 9 Participants — p=.602

Primary: Opioid Consumption in the Immediate Postoperative Period — 12.0; 14.4 morphine mg equivalents

Primary: Safety of DC Vaccine Combined With Chemotherapy — 10 Participants

Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks — 0; 6.1 Percentage of participants

Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 19.0; 35.4; 40.2 percentage of participants — p=0.009

Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -1.0; 13.0 percentage points — p=<0.0001

Primary: Number of Participants With Age Less Than or Equal to (<=) 65 Years and Greater Than (>) 65 Years at Initiation of Axitinib Treatment: Long Responders Versus Refractory…

Primary: Safety and Tolerability of Treatment as Measured by Incidence of Grade 3-4 Adverse Events Occurring in >5% of Participants — 32; 28; 26; 22 Participants

Primary: Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…

Primary: Safety of Cell Delivery — 1; 0 adverse events

Primary: Relative Change From Baseline in Whole Liver Fat at Day 15 as Assessed by Magnetic Resonance Imaging (MRI) - Proton Density Fat Fraction (PDFF) — -10.94; -32.62; -41.14…

Primary: Acceptable Lens Fitting — 0.974 Proportion of subjects

Primary: Change in Memory Change — 0.32; 0.24 z-score

Primary: Average Pain — 2.7; 3.4 score on a scale